Association between Proton Pump Inhibitors and Hearing Impairment: A Nested Case-Control Study

et al. 2022

Alz Res Therapy

Self Cite

Background Safety concerns against the use of proton pump inhibitors (PPIs) based on the risk of dementia, especially Alzheimer’s disease (AD), remain controversial. Here, we investigated the likelihood of AD depending on previous PPI exposure, use duration, and PPI generation. Methods This nested case–control study comprised 17,225 AD patients who were 1:4 matched with 68,900 controls for age, sex, income, and region of residence from Korean National Health Insurance Service-Health Screening Cohort data between 2002 and 2015 using propensity-score matching method. Conditional and unconditional logistic regression analyses were used to evaluate the effects of previous PPI use on AD adjusting for multiple covariates. Results Prior PPI use increased likelihood for AD in current and past PPI users (adjusted odds ratio 1.36 [95% confidence interval (CI) = 1.26–1.46] and 1.11 [95% CI = 1.04–1.18], respectively). Participants with either < 30 days, 30–90 days, or > 90 days of PPI prescription showed higher odds for AD (1.13 [95% CI = 1.07–1.19]; 1.18 [95% CI = 1.10–1.27]; 1.26 [95% CI = 1.16–1.36], respectively). Participants with either 1st-generation or 2nd-generation PPIs demonstrated higher incidences of AD in those with < 30 days (1.14 [95% CI = 1.07–1.22] and 1.13 [95% CI = 1.05–1.22], respectively), 30–90 days (1.19 [95% CI = 1.09–1.30] and 1.17 [95% CI = 1.05–1.29], respectively), or > 90 days (1.18 [95% CI = 1.07–1.30] and 1.27 [95% CI = 1.14–1.43], respectively) of prescription. Conclusions Prior PPI use, regardless of current or past exposure, duration of use, or use of 1st- or 2nd-generation PPIs, may increase likelihood of AD, providing supportive evidence of previous pharmacoepidemiologic studies.

Section: Exposure (Use Of Ppi)mentioning

confidence: 99%

Associations between proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening cohort

Choi

et al. 2022

Alz Res Therapy

Self Cite

“…The long-term use of PPIs was suggested to accelerate the progression of hearing loss [ 29 ]. In addition, other case-control studies reported a higher risk of hearing loss in PPI users [ 30 , 31 ]. Compared to non-PPI users, PPI users demonstrated a 1.50 times higher risk of hearing loss or tinnitus [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Association between Benign Paroxysmal Positional Vertigo and Previous Proton Pump Inhibitor Use: A Nested Case–Control Study Using a National Health Screening Cohort

Yoo

Kwon

et al. 2022

IJERPH

Self Cite

The present nested case–control study evaluated the impact of previous proton pump inhibitor (PPI) prescription on the risk of benign paroxysmal positional vertigo (BPPV). A ≥40-year-old Korean population was included. A total of 34,441 patients with BPPV was matched with 137,764 comparison participants for demographic and socioeconomic factors. Previous histories of PPI use and PPI prescription dates were compared between the BPPV and comparison groups. The odds ratios (ORs) with 95% confidence intervals (CIs) of PPI use for BPPV were calculated using a logistic regression. The demographic and socioeconomic factors and comorbidities were adjusted in the adjusted model. Both current and past PPI users were associated with higher odds for BPPV than non-PPI users (adjusted OR (aOR) = 3.57, 95% CI = 3.33–3.83, and p < 0.001 for current PPI users and aOR = 1.76, 95% CI = 1.64–1.89, and p < 0.001 for past PPI users). In addition, longer dates of PPI use were related to higher odds for BPPV (aOR (95% CI) = 1.95 [1.81–2.10] for ≥1 day and <30 days of PPI prescription, <2.88 [2.68–3.10] for ≥30 days and <365 days of PPI prescription, and <3.45 [3.19–3.73] for ≥365 days of PPI prescription). PPI use was linked with an elevated risk of BPPV in the adult population. The odds for BPPV were higher in patients with a longer duration of PPI use.

“…The days of PPI use were de ned as the total prescription days during the 1 year before the index date [24]. The prescription of PPI was classi ed as nonuser, current PPI use (prescribed at least once within the previous 30 days), and past PPI use (prescribed at least once within the previous 31-365 days).…”

Section: Exposure (Use Of Ppi)mentioning

confidence: 99%

Associations between proton pump inhibitors and Alzheimer’s disease: A nested case-control study using a Korean nationwide health screening cohort

Kwon

et al. 2022

Preprint

Self Cite

Background: Safety concerns against the use of proton pump inhibitors (PPIs) based on the risk of dementia, especially Alzheimer’s disease (AD), remain controversial. Here, we investigated the risk of AD depending on previous PPI exposure, use duration, and PPI generation.Methods: This nested case-control study comprised 17,225 AD patients who were 1:4 matched with 68,900 controls for age, sex, income, and region of residence from Korean National Health Insurance Service-Health Screening Cohort data between 2002 and 2015 using propensity-score matching method. Conditional and unconditional logistic regression analyses were used to evaluate the effects of previous PPI use on AD adjusting for multiple covariates.Results: Prior PPI use increased likelihood for AD in current and past PPI users (adjusted odds ratio 1.36 [95% CI=1.26–1.46] and 1.11 [95% CI=1.04–1.18], respectively). Participants with either <30 days, 30–90 days, or >90 days of PPI prescription showed higher odds for AD (1.13 [95% CI=1.07–1.19]; 1.18 [95% CI=1.10–1.27]; 1.26 [95% CI=1.16–1.36], respectively). Participants with either 1st-generation or 2nd-generation PPIs demonstrated higher incidences of AD in those with <30 days (1.14 [95% CI=1.07–1.22] and 1.13 [95% CI=1.05–1.22], respectively), 30–90 days (1.19 [95% CI=1.09–1.30] and 1.17 [95% CI=1.05–1.29], respectively), or >90 days (1.18 [95% CI=1.07–1.30] and 1.27 [95% CI=1.14–1.43], respectively) of prescription.Conclusions: Prior PPI use, regardless of current or past use, duration of use, or use of 1st- or 2nd-generation PPIs, may increase risk of AD, providing supportive evidence of previous pharmacoepidemiologic studies.